Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a biopharmaceutical company focused on developing therapies for patients with cardiovascular diseases and unmet medical needs. The company is advancing programs intended to address critical treatment gaps while improving outcomes for patients requiring specialized cardiovascular care.

Discussion topics include the company’s clinical development efforts, business strategy, growth initiatives, market opportunities, and long-term outlook.

This company webcast was recorded during the Lytham Partners Spring 2026 Investor Conference.